80 related articles for article (PubMed ID: 9161720)
21. The structural variations of epsilon-amino groups in phospholipase A2 enzymes from Naja naja atra and Bungarus multicinctus venoms.
Chang LS; Lin SR; Chang CC
J Protein Chem; 1997 Feb; 16(2):133-7. PubMed ID: 9112606
[TBL] [Abstract][Full Text] [Related]
22. Mutations on N-terminal region of Taiwan cobra phospholipase A(2) result in structurally distorted effects.
Chiou YL; Lin SR; Chang LS
J Pept Sci; 2008 Aug; 14(8):890-7. PubMed ID: 18288787
[TBL] [Abstract][Full Text] [Related]
23. Sequence-induced trimerization of phospholipase A2: structure of a trimeric isoform of PLA2 from common krait (Bungarus caeruleus) at 2.5 A resolution.
Singh G; Gourinath S; Saravanan K; Sharma S; Bhanumathi S; Betzel Ch; Srinivasan A; Singh TP
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2005 Jan; 61(Pt 1):8-13. PubMed ID: 16508078
[TBL] [Abstract][Full Text] [Related]
24. Structural analysis of phospholipase A2 from functional perspective. 1. Functionally relevant solution structure and roles of the hydrogen-bonding network.
Yuan C; Byeon IJ; Li Y; Tsai MD
Biochemistry; 1999 Mar; 38(10):2909-18. PubMed ID: 10074343
[TBL] [Abstract][Full Text] [Related]
25. Chemical modification of Lys-6 in Taiwan cobra phospholipase A2 with 4-chloro-3,5-dinitrobenzoate.
Chang LS; Hung JJ; Lin S; Chang CC
Biochem Mol Biol Int; 1994 Aug; 33(6):1207-13. PubMed ID: 7804147
[TBL] [Abstract][Full Text] [Related]
26. Interfacial recognition by bee venom phospholipase A2: insights into nonelectrostatic molecular determinants by charge reversal mutagenesis.
Ghomashchi F; Lin Y; Hixon MS; Yu BZ; Annand R; Jain MK; Gelb MH
Biochemistry; 1998 May; 37(19):6697-710. PubMed ID: 9578553
[TBL] [Abstract][Full Text] [Related]
27. Heparin prevents the binding of phospholipase A2 to phospholipid micelles: importance of the amino-terminus.
Diccianni MB; Lilly-Stauderman M; McLean LR; Balasubramaniam A; Harmony JA
Biochemistry; 1991 Sep; 30(37):9090-7. PubMed ID: 1892820
[TBL] [Abstract][Full Text] [Related]
28. Crystal structure of the complex of bovine pancreatic phospholipase A2 with the inhibitor 1-hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol,
Sekar K; Eswaramoorthy S; Jain MK; Sundaralingam M
Biochemistry; 1997 Nov; 36(46):14186-91. PubMed ID: 9369492
[TBL] [Abstract][Full Text] [Related]
29. Crystal structure of the Y52F/Y73F double mutant of phospholipase A2: increased hydrophobic interactions of the phenyl groups compensate for the disrupted hydrogen bonds of the tyrosines.
Sekharudu C; Ramakrishnan B; Huang B; Jiang RT; Dupureur CM; Tsai MD; Sundaralingam M
Protein Sci; 1992 Dec; 1(12):1585-94. PubMed ID: 1304890
[TBL] [Abstract][Full Text] [Related]
30. Structural elements of ligand recognition site in secretory phospho-lipase A2 and structure-based design of specific inhibitors.
Singh N; Somvanshi RK; Sharma S; Dey S; Kaur P; Singh TP
Curr Top Med Chem; 2007; 7(8):757-64. PubMed ID: 17456039
[TBL] [Abstract][Full Text] [Related]
31. Interaction of monodisperse anionic amphiphiles with the i-face of secreted phospholipase A2.
Yu BZ; Apitz-Castro R; Tsai MD; Jain MK
Biochemistry; 2003 May; 42(20):6293-301. PubMed ID: 12755634
[TBL] [Abstract][Full Text] [Related]
32. Crystal structure of an acidic phospholipase A2 from the venom of Agkistrodon halys pallas at 2.0 A resolution.
Wang XQ; Yang J; Gui LL; Lin ZJ; Chen YC; Zhou YC
J Mol Biol; 1996 Feb; 255(5):669-76. PubMed ID: 8636969
[TBL] [Abstract][Full Text] [Related]
33. Phospholipase A2 engineering. The structural and functional roles of aromaticity and hydrophobicity in the conserved phenylalanine-22 and phenylalanine-106 aromatic sandwich.
Dupureur CM; Yu BZ; Mamone JA; Jain MK; Tsai MD
Biochemistry; 1992 Nov; 31(43):10576-83. PubMed ID: 1420172
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human synovial fluid phospholipase A2 and N-terminal variant: kinetic parameters and response to inhibitors.
Märki F; Hanulak V
J Biochem; 1993 Jun; 113(6):734-7. PubMed ID: 8370672
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human secretory phospholipase A2: purification and characterization of the enzyme for active site studies.
Stadel JM; Jones C; Livi GP; Hoyle K; Kurdyla J; Roshak A; McLaughlin MM; Pfarr DA; Comer S; Strickler J
J Mol Recognit; 1992 Dec; 5(4):145-53. PubMed ID: 1339483
[TBL] [Abstract][Full Text] [Related]
36. Enhancing activity and phospholipase A2 activity: two independent activities present in the enhancing factor molecule.
Kadam S; Mulherkar R
Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):237-43. PubMed ID: 10229680
[TBL] [Abstract][Full Text] [Related]
37. Contributions of residues of pancreatic phospholipase A2 to interfacial binding, catalysis, and activation.
Yu BZ; Rogers J; Tsai MD; Pidgeon C; Jain MK
Biochemistry; 1999 Apr; 38(15):4875-84. PubMed ID: 10200177
[TBL] [Abstract][Full Text] [Related]
38. Receptor-binding capability of pancreatic phospholipase A2 is separable from its enzymatic activity.
Ishizaki J; Kishino J; Teraoka H; Ohara O; Arita H
FEBS Lett; 1993 Jun; 324(3):349-52. PubMed ID: 8405380
[TBL] [Abstract][Full Text] [Related]
39. Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes.
Weiss J; Inada M; Elsbach P; Crowl RM
J Biol Chem; 1994 Oct; 269(42):26331-7. PubMed ID: 7929350
[TBL] [Abstract][Full Text] [Related]
40. Mapping the interfacial binding surface of human secretory group IIa phospholipase A2.
Snitko Y; Koduri RS; Han SK; Othman R; Baker SF; Molini BJ; Wilton DC; Gelb MH; Cho W
Biochemistry; 1997 Nov; 36(47):14325-33. PubMed ID: 9398150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
